[go: up one dir, main page]

MA48791A - Combinaisons pharmaceutiques de zonisamide et de praxipexole, et procédés associés, pour le traitement de synucléinopathies - Google Patents

Combinaisons pharmaceutiques de zonisamide et de praxipexole, et procédés associés, pour le traitement de synucléinopathies

Info

Publication number
MA48791A
MA48791A MA048791A MA48791A MA48791A MA 48791 A MA48791 A MA 48791A MA 048791 A MA048791 A MA 048791A MA 48791 A MA48791 A MA 48791A MA 48791 A MA48791 A MA 48791A
Authority
MA
Morocco
Prior art keywords
praxipexole
synucleinopathies
zonisamide
treatment
related processes
Prior art date
Application number
MA048791A
Other languages
English (en)
Inventor
Thomas N Chase
Kathleen E Clarence-Smith
Original Assignee
Chase Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Therapeutics Corp filed Critical Chase Therapeutics Corp
Publication of MA48791A publication Critical patent/MA48791A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA048791A 2017-05-26 2018-05-23 Combinaisons pharmaceutiques de zonisamide et de praxipexole, et procédés associés, pour le traitement de synucléinopathies MA48791A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762511424P 2017-05-26 2017-05-26

Publications (1)

Publication Number Publication Date
MA48791A true MA48791A (fr) 2020-04-08

Family

ID=64397000

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048791A MA48791A (fr) 2017-05-26 2018-05-23 Combinaisons pharmaceutiques de zonisamide et de praxipexole, et procédés associés, pour le traitement de synucléinopathies

Country Status (7)

Country Link
US (1) US20200138792A1 (fr)
EP (1) EP3630289A4 (fr)
AU (1) AU2018271895A1 (fr)
CA (1) CA3099090A1 (fr)
MA (1) MA48791A (fr)
TW (1) TW201900163A (fr)
WO (1) WO2018217845A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020139520A1 (fr) * 2018-12-27 2020-07-02 Chase Therapeutics Corporation Combinaisons anti-neurodégénératives à base de dompéridone et leur utilisation
TWI870475B (zh) * 2019-10-02 2025-01-21 美商卡凡恩公司 用於治療神經毒性之方法及材料

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032661A1 (en) * 2001-08-02 2003-02-13 Boehringer Ingelheim Pharma Kg Pramipexole as an anticonvulsant
WO2008010768A1 (fr) * 2006-07-17 2008-01-24 Cereuscience Ab Méthode de traitement et de diagnostic du syndrome des jambes sans repos et de mouvements involontaires des membres pendant le sommeil et moyen pour la mise en oeuvre de ladite méthode
WO2009054543A1 (fr) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Antagonistes du récepteur ampa et zonisamide destinés à traiter la maladie de parkinson et les troubles moteurs
NZ589304A (en) * 2008-04-29 2012-03-30 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
WO2010010138A1 (fr) * 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Composition pharmaceutique renfermant du pramipexole et un inhibiteur des canaux calciques pour le traitement de la maladie de parkinson

Also Published As

Publication number Publication date
TW201900163A (zh) 2019-01-01
CA3099090A1 (fr) 2018-11-29
EP3630289A1 (fr) 2020-04-08
WO2018217845A1 (fr) 2018-11-29
US20200138792A1 (en) 2020-05-07
EP3630289A4 (fr) 2021-03-03
AU2018271895A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
MA49144A (fr) Polythérapies pour le traitement du cancer
MA71705A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
MA42439A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3533466A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
EP3635130A4 (fr) Médicament de précision pour le traitement et la prévention du risque suicidaire
EP3503890A4 (fr) Utilisation de la pridopidine pour le traitement des dystonies
EP3400011A4 (fr) Combinaisons anti-cd20 pour le traitement des tumeurs
EP3766497A4 (fr) Médicament pour le traitement de la toux
EP3358929A4 (fr) Procédés et appareils pour le traitement d'une matière agricole
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3423048A4 (fr) Polythérapie pour le traitement du cancer de l'ovaire
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
MA46086A (fr) Schéma posologique pour le traitement de tumeurs solides
EP3426254A4 (fr) Utilisation d'inhibiteurs de braf pour le traitement de réactions cutanées
EP3365014A4 (fr) Méthodes et compositions pour le traitement de la mastocytose systémique
EP3684933A4 (fr) Oligonucléotides thiomorpholino pour le traitement de la dystrophie musculaire